期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 69, 期 21, 页码 2646-2656出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.04.014
关键词
blood glucose; cardiovascular disease; heart failure; hypoglycemic agents; outcomes
资金
- AstraZeneca
- Amgen
- Sanofi
- Boehringer Ingelheim
- Eli Lilly
- Novo Nordisk
- Janssen
- Takeda
- Novartis
- Maquet
- Pfizer
- Daiichi-Sankyo
- Servier
- Hutter Family Professorship
- Siemens
- Singulex
- Prevencio
Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics. The sodium-glucose cotransporter 2 inhibitor, empagliflozin, markedly and rapidly reduced CV death and heart failure hospitalization, likely with hemodynamic/metabolic-driven mechanisms of action. More recently, the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide also reduced CV death and/or major adverse CV events, but did so more slowly and did not influence heart failure risks, suggesting alternative mechanisms of benefit. We will discuss drug therapy for diabetes relative to CV risk, briefly summarize key findings of CV benefit from recent trials, discuss potential mechanisms for benefits of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, and suggest how such drugs might be embraced by CV specialists to reduce CV events and mortality in their patients. (J Am Coll Cardiol 2017;69:2646-56) (C) 2017 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据